You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Interferon gamma therapy and pulmonary fibrosis
  1. A R L Medford
  1. Clinical Research Fellow and Honorary Specialist Registrar, University of Bristol, Southmead Hospital, Bristol, UK; andrew.medford@bristol.ac.uk

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    ▴ Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med2004;350:125–33
    OpenUrlCrossRefPubMedWeb of Science

    In this double blind multinational study, 330 patients with idiopathic pulmonary fibrosis were randomly assigned to treatment with either subcutaneous interferon gamma-1b (n = 162) or placebo (n = 168) three times daily for 48 weeks. Interferon gamma-1b had no significant effect on the primary end point (disease progression or death) compared with placebo. 10% …

    View Full Text